Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nasopharynx

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Nasopharynx. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-001530-14 Sponsor Protocol Number: NPC 2006 Start Date*: 2007-10-12
    Sponsor Name:GORTEC [...]
    1. GORTEC
    2.
    Full Title: Essai de Phase III, Multicentrique, Randomisé, comparant la Chimiothérapie d’induction par Docétaxel, Cisplatine et 5-Fluorouracile (TPF) suivie d’une chimio-radiothérapie concomitante versus une c...
    Medical condition: Patients atteints de cancers du nasopharynx classés T2b; T3;T4 ; OMS II-III et /ou avec envahissement ganglionnaire (Nsupérieur ou égal à 1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026161 Malignant neoplasm of nasopharynx LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001211-33 Sponsor Protocol Number: EFC10339 Start Date*: 2007-06-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyng...
    Medical condition: Children and adolescents newly diagnosed with NPC with measurable disease T2-T4 any NM, of <18 years of age at the time of diagnosis. ---------- Niños y adolescentes recien diagnosticados con CNF c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) FR (Completed) IT (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012225-12 Sponsor Protocol Number: 64-Cu-ATSM-CC-02/2009 Start Date*: 2009-09-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in head and neck cancer
    Medical condition: head and neck cancer. MEDRA code has not been found.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026184 LLT
    9.1 10026161 LLT
    9.1 10025963 LLT
    9.1 10025923 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001745-25 Sponsor Protocol Number: CC-486-NPC-001 Start Date*: 2015-01-22
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastati...
    Medical condition: Locally advanced or metastatic nasopharyngeal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005017-31 Sponsor Protocol Number: DERN Start Date*: 2019-01-29
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY
    Medical condition: advanced or metastatic Nose Pharynx Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004649-35 Sponsor Protocol Number: POINT Start Date*: 2021-12-14
    Sponsor Name:Fondazione GONO
    Full Title: Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer
    Medical condition: Nasopharyngeal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000230-29 Sponsor Protocol Number: CA209-358 Start Date*: 2015-09-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors
    Medical condition: Virus-associated tumors
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046885 Vaginal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061306 Nasopharyngeal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047777 Vulvar cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001416-27 Sponsor Protocol Number: MEC-2012-130 Start Date*: 2012-11-15
    Sponsor Name:Erasmus MC
    Full Title: Treatment of Cancer in the head and Neck: The Role of Hyperbaric Oxygen in Reducing Swallowing Problems
    Medical condition: Nasopharynx, Oropharynx, Oral Cavity, Hypopharynx, Larynx
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022444-20 Sponsor Protocol Number: 40-41200-98-9069 Start Date*: 2010-11-15
    Sponsor Name:ZonMW
    Full Title: PHASE I-II STUDY OF GEMCITABINE AND VALPROIC ACID PLUS VALGANCICLOVIR IN PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA
    Medical condition: Patient has histological confirmed residual, recurrent or metastatic EBV-positive Nasopharynx carcinoma that has failed conventional curative treatments and deemed incurable, or patient refuses fur...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011758-16 Sponsor Protocol Number: 1.1 Start Date*: 2009-12-16
    Sponsor Name:Karolinska University Hospital Huddinge
    Full Title: A randomized placebo controlled trial of vitamin D3 supplementation to a vulnerable patientsgroup susceptible to uppertract respiratory infections.
    Medical condition: Patients with primary or secondary immunodeficiencies and/or patients who have an increased incidence of airborn infections more than 42 infectionsday /year.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001849-39 Sponsor Protocol Number: NETs-C19 Start Date*: 2020-05-18
    Sponsor Name:Region Skåne
    Full Title: Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial
    Medical condition: SARS-coronavirus-2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003381-33 Sponsor Protocol Number: EMR-62202-717 Start Date*: 2007-08-30
    Sponsor Name:Institute of Oncology Ljubljana
    Full Title: Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.
    Medical condition: Inoperable squamous cell carcinoma of the head and neck.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001270-29 Sponsor Protocol Number: EFC16858 Start Date*: 2020-04-08
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19
    Medical condition: Coronavirus infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001890-56 Sponsor Protocol Number: COVID-Γ Start Date*: 2020-06-10
    Sponsor Name:Universidad Católica de Murcia (UCAM)
    Full Title: Double-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19
    Medical condition: Patients with severe symptoms of COVID-19, a disease caused by infection with the SARS-CoV-2 virus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000392-14 Sponsor Protocol Number: 1200.131 Start Date*: 2011-07-27
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: LUX-Head & Neck 2 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary...
    Medical condition: Loco-regionally advanced head and neck squamous cell carcinoma with no evidence of disease after chemo-radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DE (Completed) FI (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IT (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005816-29 Sponsor Protocol Number: 2006-002-0201-ONC Start Date*: 2008-06-17
    Sponsor Name:Royal Wolverhampton Hospitals Trust
    Full Title: A Pilot Study of Taxotere (Docetaxel), Cisplatin and 5FU (TPF) in the Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Locally recurrent or metastatic squamous call carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004799-50 Sponsor Protocol Number: PNEUMOREG Start Date*: 2015-02-13
    Sponsor Name:Federico Martinon Torres
    Full Title: Evaluation of the immunoregulatory role of pneumococcal conjugate vaccination in pediatric patients with allergic asthma or type 1 diabetes mellitus versus pediatric population control.
    Medical condition: Allergic asthma and type 1 diabetes mellitus in pediatric subjects.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001458-24 Sponsor Protocol Number: VAC-264 Start Date*: 2012-09-03
    Sponsor Name:RIVM
    Full Title: Cross-sectional surveillance study on pneumococcal serotypes and other pathogens in nasopharyngeal samples from infants and parents performed 6.5 years after introduction of pneumococcal vaccinatio...
    Medical condition: The study investigates the presence of nasopharyngeal vaccine- and non-vaccine pneumococcal serotypes in 11- and 24-month-old infants and parents, 6.5 years after implementation of a pneumococcal v...
    Disease:
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000414-38 Sponsor Protocol Number: ET18-023 Start Date*: 2019-01-30
    Sponsor Name:Centre Léon Bérard
    Full Title: Frail-Immune (GORTEC-2018-03) - A multicenter, prospective, single arm phase II study evaluating the efficacy and safety of the combination of Durvalumab with carboplatin and paclitaxel as first li...
    Medical condition: Patient with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are not eligible to standard first line chemotherapy
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001623-11 Sponsor Protocol Number: OOI/FNY/2005-1 Start Date*: 2006-09-07
    Sponsor Name:National Institute of Oncology
    Full Title: Docetaxellel bövített standard 5-fluorouracil plusz ciszplatin alapú neoadjuváns kemoterápia plusz ciszplatin alapú radiokemoterápia összehasonlítása a standard ciszplatin alapú radiokemoterápiáva...
    Medical condition: Beteganyag III-IV. stádiumú, laphámrák szövettanú szájüreg-, nyelv-, gingíva-, sublingua-, (ajak nem), szájgarat-, algarat- és gégetumoros betegek. (A betegek az Országos Onkológiai Intézet Fej-nya...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:38:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA